Global burden of cancers attributable to infections in 2012: a synthetic analysis

Plummer, Martyn; Martel, Catherine de; Vignat, Jérôme; Ferlay, ME Jacques; Bray, Freddie; Franceschi, Silvia

doi:10.1016/s2214-109x(16)30143-7

Cited by 1,341 publications

(1,136 citation statements)

References 22 publications

Supporting

Mentioning

994

Contrasting

Unclassified

Order By: Relevance

“…Plant terpenoids are extensively used for their aromatic qualities and have played a role in traditional herbal remedies in India and China [10,11].…”

Section: Medicinal Plants Have Been Used Orally and As --------------mentioning

confidence: 99%

Identification of novel anticancer terpenoids from <i>Prosopis juliflora</i> (Sw) DC (Leguminosae) pods

Malik¹,

Ahmed²,

Khan³

2018

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

“…Plant terpenoids are extensively used for their aromatic qualities and have played a role in traditional herbal remedies in India and China [10,11].…”

Section: Medicinal Plants Have Been Used Orally and As --------------mentioning

confidence: 99%

Identification of novel anticancer terpenoids from <i>Prosopis juliflora</i> (Sw) DC (Leguminosae) pods

Malik¹,

Ahmed²,

Khan³

2018

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

“…Bacteria and multicellular parasites are responsible for a fraction of these infection-related cancers, but the majority is associated with viral infection. At least 1.3 million new cases of cancer worldwide every year, or 10%-12% of the total number of new diagnoses, are likely related to viral infection [1,2]. If these virus-associated tumors were prevented, there would be 19% fewer cancers in developing countries and 3.8% fewer in developed countries [1].…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy against cancer-related viruses

2016

View full text Add to dashboard Cite

Approximately 12% of all cancers worldwide are associated with viral infections. To date, eight viruses have been shown to contribute to the development of human cancers, including Epstein-Barr virus (EBV), Hepatitis B and C viruses, and Human papilloma virus, among others. These DNA and RNA viruses produce oncogenic effects through distinct mechanisms. First, viruses may induce sustained disorders of host cell growth and survival through the genes they express, or may induce DNA damage response in host cells, which in turn increases host genome instability. Second, they may induce chronic inflammation and secondary tissue damage favoring the development of oncogenic processes in host cells. Viruses like HIV can create a more permissive environment for cancer development through immune inhibition, but we will focus on the previous two mechanisms in this review. Unlike traditional cancer therapies that cannot distinguish infected cells from non-infected cells, immunotherapies are uniquely equipped to target virus-associated malignancies. The targeting and functioning mechanisms associated with the immune response can be exploited to prevent viral infections by vaccination, and can also be used to treat infection before cancer establishment. Successes in using the immune system to eradicate established malignancy by selective recognition of virus-associated tumor cells are currently being reported. For example, numerous clinical trials of adoptive transfer of ex vivo generated virus-specific T cells have shown benefit even for established tumors in patients with EBV-associated malignancies. Additional studies in other virus-associated tumors have also been initiated and in this review we describe the current status of immunotherapy for virus-associated malignancies and discuss future prospects.

show abstract

“…Also, 65% of cancer deaths have occurred in developing countries [1] . Furthermore, the incidence of cancer-related mortality in developing countries all over the world is expected to even rise significantly in the near future, due to lifestyle changes and multiple environmental factors, and it has recently been projected that in 2020 more than 60% of cancer cases will occur in developing countries causing more deaths than AIDS, malaria, and tuberculosis together [2][3][4] . Despite this data, there is no doubt that there are significant disparities in access to cancer care and cancer control between developing nations and higher income countries.…”

Section: Introductionmentioning

confidence: 99%

Challenges, hurdles and possible approaches to improve cancer care in developing countries – A short breakdown of the status quo and future perspective

Brookman‐May¹,

Rodríguez-Faba²,

Langenhuijsen³

et al. 2017

Adv Mod Oncol Res

View full text Add to dashboard Cite

Abstract:It was estimated that in 2012, 57% of the incidence and 65% of cancer deaths have occurred in developing countries, and in the future, the incidence of cancer-related mortality is even expected to rise significantly in these countries. Despite this alarming data, there are still significant disparities in access to cancer care and cancer control between developing nations and higher income countries. There are several hurdles for cancer patients in developing countries which impair adequate treatment, including very little access to programs of cancer prevention and screening measures, early diagnosis and adequate surgical and medical tumor treatment. In this article, we provide a short assessment and breakdown of the main barriers for proper cancer treatment admission and provide a perspective on potential approached and solutions to enhance cancer research and care in developing countries.

show abstract

Global burden of cancers attributable to infections in 2012: a synthetic analysis

Abstract: Fondation de France.

Cited by 1,341 publications

References 22 publications

Identification of novel anticancer terpenoids from <i>Prosopis juliflora</i> (Sw) DC (Leguminosae) pods

Identification of novel anticancer terpenoids from <i>Prosopis juliflora</i> (Sw) DC (Leguminosae) pods

Immunotherapy against cancer-related viruses

Challenges, hurdles and possible approaches to improve cancer care in developing countries – A short breakdown of the status quo and future perspective

Contact Info

Product

Resources

About